Form 4: Nuvation Bio Insider Trades Class A Stock

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., reported transactions involving Class A Common Stock, including purchases and sales executed under a 10b5-1 plan.

Summary

• Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc., engaged in several transactions involving Class A Common Stock on April 6, 2026.
• These transactions included the acquisition of 100,000 shares at $1.87 and another 100,000 shares at $1.94.
• Additionally, 200,000 shares were sold at a weighted-average price of $4.5178, with individual sales ranging from $4.44 to $4.64.
• The sale of 200,000 shares was conducted under a Rule 10b5-1 trading plan established on December 4, 2025.
• Following these transactions, Wentworth's beneficial ownership of Class A Common Stock stands at 53,000 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the transaction being conducted under a pre-arranged 10b5-1 plan.

Positives

• Acquisition of 200,000 shares at prices below the subsequent sale price, indicating potential for profit.
• The sale was executed under a pre-arranged 10b5-1 plan, suggesting a structured approach to managing stock holdings and avoiding insider trading concerns.

Negatives

• A significant number of shares (200,000) were sold, potentially signaling a lack of strong conviction in immediate price appreciation by a key executive.
• The sale price ($4.5178 weighted average) is considerably lower than the peak prices seen in the market, though the filing does not provide historical price context for this specific period.

Risks

• The sale of a substantial number of shares by a Chief Regulatory Officer could be interpreted negatively by the market, potentially impacting investor sentiment.
• The effectiveness of the 10b5-1 plan relies on its adherence to regulatory requirements, and any deviation could lead to scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The sale of 200,000 shares was conducted pursuant to a 10b5-1 plan dated December 4, 2025.
• The weighted-average sales price for the disposed shares was $4.5178, with actual prices ranging from $4.44 to $4.64.
• The reporting person will provide full information regarding the number of shares sold at each separate price upon request to the SEC, the Issuer, or a security holder.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes create short-term negative sentiment for a stock, particularly if the volume is significant relative to the executive's holdings or the company's float. However, the existence of a 10b5-1 plan is designed to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders may react to the significant sale by a senior executive, potentially leading to short-term price fluctuations.
• Employees holding stock options or shares may be influenced by insider trading patterns.
• The Issuer (Nuvation Bio Inc.) may need to address any investor concerns arising from the transaction.

Next Steps

• The reporting person may continue to execute trades under the existing 10b5-1 plan if applicable.
• The market will likely observe future trading activity by insiders for further indications of sentiment.

Key Dates

Recommendation

The filing reports routine insider transactions under a 10b5-1 plan. While the sale of a significant number of shares by a key executive could be a minor concern, the structured nature of the sale under a pre-defined plan suggests it's not necessarily a bearish signal. Without additional financial or strategic information from Nuvation Bio, a 'hold' recommendation is prudent, advising investors to monitor further developments and the company's overall performance.

Keywords

Nuvation Bio, NUVB, Form 4, Insider Trading, Class A Common Stock, 10b5-1 Plan, Kerry Wentworth, Stock Sale, Stock Purchase, Beneficial Ownership